Virexxa (sodium cridanimod) / Pharmsynthez, Xenetic Biosci - LARVOL DELTA

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - P2 | N=25 | Terminated | Sponsor: Xenetic Biosciences, Inc. | N=36 ➔ 25 | Completed ➔ Terminated; The study was discontinued due to a change in development strategy and not due safety concern.

Enrollment change • Trial termination • Endometrial Cancer • Oncology • Solid Tumor

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - P2; N=36; Completed; Sponsor: Xenetic Biosciences, Inc.; Active, not recruiting ➔ Completed; N=72 ➔ 36; Trial completion date: Jan 2021 ➔ Jul 2020; Trial primary completion date: Jan 2021 ➔ Jul 2020

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Endometrial Cancer • Gynecologic Cancers • Oncology • Solid Tumor • MRI